A Prospective, Open-label, Single Center, Dose Finding Phase I-study With Atu027 (an siRNA Formulation) in Subjects With Advanced Solid Cancer.
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2014
At a glance
- Drugs ATU 027 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Silence Therapeutics AG
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jun 2012 Enrolment in the tenth and final dose cohort has been completed and the final treatment is scheduled for 22 June 2012.
- 06 Jun 2012 Results were reported at the 48th Annual Meeting of the American Society of Clinical Oncology, and in a Silence Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History